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Diabetes is associated with an increased mortality risk due to cardiovascular
complications. Hyperglycemia-induced oxidative stress underlies these complications,
leading to an impairment in endogenous nitric oxide (NO•) generation, together with
reductions in NO• bioavailability and NO• responsiveness in the vasculature, platelets and
myocardium. The latter impairment of responsiveness to NO•, termed NO• resistance,
compromises the ability of traditional NO•-based therapeutics to improve hemodynamic
status during diabetes-associated cardiovascular emergencies, such as acute myocardial
infarction. Whilst a number of agents can ameliorate (e.g. angiotensin converting enzyme
[ACE] inhibitors, perhexiline, statins and insulin) or circumvent (e.g. nitrite and sGC
activators) NO• resistance, nitroxyl (HNO) donors offer a novel opportunity to
circumvent NO• resistance in diabetes. With a suite of vasoprotective properties and
an ability to enhance cardiac inotropic and lusitropic responses, coupled with preserved
efficacy in the setting of oxidative stress, HNO donors have intact therapeutic potential in
the face of diminished NO• signaling. This review explores the major mechanisms by
which hyperglycemia-induced oxidative stress drives NO• resistance, and the therapeutic
potential of HNO donors to circumvent this to treat cardiovascular complications in type 2
diabetes mellitus.
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Globally, over 460 million individuals have diabetes, and this figure is projected to increase to 700
million by the year 2045 (Saeedi et al., 2019). It is estimated that 90% of these individuals have type 2
diabetes mellitus (T2DM), and approximately 10% have type 1 diabetes mellitus (T1DM)
(International Diabetes Federation, 2019). The leading cause of morbidity and mortality in
individuals with either diabetes subtype is cardiovascular disease (Htay et al., 2019). Individuals
with diabetes have an elevated risk of coronary artery disease, peripheral vascular disease, ischemic
stroke and heart failure (Almourani et al., 2019). These cardiovascular complications arise largely as
a consequence of hyperglycemia-induced oxidative stress, which impairs nitric oxide (NO•)in.org May 2020 | Volume 11 | Article 7271
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et al., 2013). This loss in NO• responsiveness, termed ‘NO•
resistance,' results largely due to “scavenging” of NO• by
superoxide and inactivation of its target, soluble guanylyl
cyclase (sGC) (Paolocci et al., 2001a; Worthley et al., 2007;
Ritchie et al., 2017). NO• resistance affects multiple sites in the
cardiovascular system, including the myocardium, vasculature
and platelets (Qin et al., 2020). As such, patients with diabetes fail
to respond to the anti-aggregatory and vasodilator effects of
NO•-based pharmacotherapies during cardiovascular
emergencies, such as acute myocardial infarction, transient
myocardial ischemia and acute decompensated heart failure
(Dautov et al., 2013). Several pharmacotherapies including
statins, some angiotensin-converting enzyme (ACE) inhibitors,
perhexil ine, and insulin (in the presence of severe
hyperglycemia) ameliorate NO• resistance (Chirkov and
Horowitz, 2007), while sGC activators primarily circumvent
the problem (Costell et al., 2012). However, there are
limitations associated with their clinical utility, particularly as
these amelioration strategies are not instantaneously effective,
and thus unsuitable for emergency situations. On the contrary,
nitroxyl (HNO) donors circumvent NO• resistance and thus
promote vasodilation, while uniquely inducing positive inotropic
and lusitropic responses that persist in conditions of oxidative
stress (e.g. heart failure, diabetes) where responses to NO• are
diminished (Paolocci et al., 2003; Chin et al., 2016; Tare et al.,
2017; Qin et al., 2020). Although the aforementioned
cardiovascular changes are associated with both T1DM and
T2DM, due to the prevalence of the latter, this review will
explore the major mechanisms that drive impairments in NO•
signaling in T2DM, and highlight the therapeutic potential of
HNO donors to circumvent this problem, in order to alleviate
acute hemodynamic complications in T2DM.NITRIC OXIDE SIGNALING IN THE
CARDIOVASCULAR SYSTEM
Nitric Oxide Synthesis
NO• plays an important role in maintaining cardiovascular
homeostasis. This occurs through its vasodilator capacity,
inhibition and reversal of platelet aggregation, suppression of
inflammation and oxidative stress, inhibition of thrombosis and
modulation of vascular smooth muscle cell (VSMC) proliferation
and vascular remodeling (Napoli et al., 2006; Ignarro, 2019).
NO• is endogenously synthesized by three isoforms of the NO•
synthase (NOS) enzyme, specifically, neuronal NOS (nNOS),
inducible NOS (iNOS) and endothelial NOS (eNOS), also known
as NOS1, NOS2 and NOS3, respectively (Salerno et al., 2018). All
three enzymes consist of two subunits, an N-terminal oxygenase
domain that binds the substrate L-arginine, cofactor
tetrahydrobiopterin (BH4) and a heme iron group, and a C-
terminal reductase domain that binds nicotinamide adenine
dinucleotide phosphate (NADPH), flavin adenine dinucleotide
phosphate (FAD) and flavin mononucleotide (FMN) (Qian and
Fulton, 2013). Between these domains, exists a calmodulinFrontiers in Pharmacology | www.frontiersin.org 2binding sequence, that binds calcium (Ca2+) (Förstermann and
Sessa, 2012).
eNOS is considered the predominant isoform constitutively
expressed in the cardiovascular system, where it is responsible for
the synthesis of NO• in endothelial cells, cardiomyocytes and
platelets (Radziwon-Balicka et al., 2017; Ritchie et al., 2017). In
endothelial cells, eNOS produces NO• in response to stimulation
by shear stress or receptor agonists including bradykinin,
acetylcholine, substance P, thrombin, histamine or b-
adrenoceptor agonists (Premer et al., 2019). Under basal
conditions, eNOS is present in an inactive state bound to
either caveolin-1 or caveolin-3, which are located in small
invaginations of the plasma membrane known as caveolae, in
endothelial cells or cardiomyocytes, respectively (Massion et al.,
2003). Upon stimulation by shear stress or agonists, intracellular
Ca2+ levels increase, leading to recruitment of the Ca2+-
calmodulin sequence, which displaces caveolin-1 or caveolin-3
from the enzyme leading to eNOS activation (Förstermann and
Sessa, 2012). Subsequently, the cofactor BH4 and heat shock
protein 90 (hsp90) are recruited, together with protein kinase B/
Akt, which phosphorylates Ser1177, thereby activating eNOS
(Sharma et al., 2012). This leads to electron transfer from
NADPH by FAD and FMN, allowing O2 to bind to the heme
iron group on eNOS, resulting in the conversion of L-arginine to
NO• and L-citrulline (Stuehr et al., 2004; Mancardi et al., 2005).
NO• is also generated from NOS-independent sources such as
from nitrite and dietary nitrate. In brief, following absorption of
dietary nitrate from the gastrointestinal tract, salivary
commensal bacteria reduce nitrate to nitrite. Nitrite can then
circulate and be converted to NO• via the nitrite reductase
activity of several proteins (e.g. deoxyhemoglobin, xanthine
oxidoreductase), providing a NOS-independent pathway for
NO• generation (Farah et al., 2018). The major physiological
modulator of eNOS activity appears to be tissue concentrations
of the competitive NOS antagonist asymmetric dimethylarginine
(ADMA) (Böger, 2004; Cooke, 2005).
Nitric Oxide Signaling in the Vasculature
NO• signals predominantly via its intracellular receptor, sGC. In
the vasculature, endothelium-derived NO• diffuses into
underlying VSMCs in a paracrine manner, where it binds to the
ferrous (Fe2+) heme iron on sGC (Mancardi et al., 2005; Korkmaz
et al., 2018). Activation of sGC leads to the production of 3,5-
cyclic guanosine monophosphate (cGMP), intracellular levels of
which are regulated by phosphodiesterases (PDEs), which
hydrolyze cGMP to GMP (Kass et al., 2007). cGMP effectors
include cGMP-dependent protein kinases (cGKs), PDEs and
cGMP-gated ion channels (Kemp-Harper and Schmidt, 2009).
cGKs phosphorylate target proteins leading to a reduction in
intracellular Ca2+ concentration, resulting in VSMC relaxation
and vasodilation, and suppression of VSMC proliferation (Kemp-
Harper and Schmidt, 2009) (Figure 1). Similarly, the anti-
aggregatory actions of NO• are mediated predominantly via the
sGC/cGMP signaling pathway. Thus NO• generated by the
endothelium diffuses into the blood vessel lumen where it
inhibits platelet aggregation, platelet adhesion to the vascular
wall, and thrombosis (Förstermann and Sessa, 2012).May 2020 | Volume 11 | Article 727
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nitrosylation: NO• reacts with thiols on cysteine residues of
target proteins, resulting in modulation of their biological
functions (Mancardi et al., 2005; Lima et al., 2010). This is of
particular relevance in the vasculature whereby NO• limits
superoxide generation via S-nitrosylation of p47phox, a critical
subunit of the reactive oxygen species (ROS)-generating enzyme,
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
2 (Nox2) (Selemidis et al., 2007), thus protecting against vascular
oxidative stress.
Moreover, NO• plays a key anti-inflammatory/anti-
atherogenic role, with an ability to limit the activation and
transmigration of monocytes through the endothelium to the
site of vascular injury via the reduction of endothelial adhesion
molecules [e.g. vascular adhesion molecule-1 (VCAM-1);
(Spiecker et al . , 1997)], chemokine [e.g. monocyte
chemoattractant protein-1 (MCP-1); (Zeiher et al., 1995)] and
cytokine expression (e.g. interleukin-6 (IL-6); (De Caterina et al.,
1995)). These actions of NO• may be explained, in part, by its
inhibitory effects on nuclear factor kappa-B (NF-kB) and NLRP3
inflammasome activation. NO• suppresses NF-kB signaling via
S-nitrosylation of its regulatory subunit and transcription factor,
IKKb and p65, respectively (Qian and Fulton, 2012). This leadsFrontiers in Pharmacology | www.frontiersin.org 3to decreased expression of pro-inflammatory and pro-
atherogenic mediators including intracellular adhesion
molecule-1 (ICAM-1), VCAM-1 (Spiecker et al., 1997; Qian
and Fulton, 2012), MCP-1 and IL-6 (De Caterina et al., 1995;
Zeiher et al., 1995). Moreover, NO• regulates the NLRP3
inflammasome, which is a multiprotein signaling complex
expressed in macrophages, that activates caspase-1, resulting in
the maturation and secretion of the pro-inflammatory cytokines,
interleukin-1b (IL-1b) and interleukin-18 (IL-18) (Chen and
Sun, 2013). NO• inhibits NLRP3 inflammasome activation, likely
via suppression of expression of the NLRP3 activator
thioredoxin-interacting protein (TXNIP) (Sverdlov et al., 2013;
Chong et al., 2015), thus decreasing caspase-1 activation and
secretion of mature IL-1b and IL-18 (Hernandez-Cuellar et al.,
2012; Mao et al., 2013). In addition, NO• also has the capacity to
limit mast cell degranulation, reducing the release of
inflammatory mediators and cytokines and thereby inhibiting
the initiation of acute vascular inflammatory processes
(Coleman, 2002).
Overall, the entire spectrum of endogenous NO• effects is
pro-homeostatic, and confers protection against both
atherosclerotic plaque development and rupture. Indeed, NO•
normally functions as a ‘firehose', dousing out the flames ofFIGURE 1 | Nitric oxide signaling in the vasculature and myocardium. In endothelial cells and cardiomyocytes, nitric oxide (NO•) is produced by endothelial nitric
oxide synthase (eNOS) following stimulation by shear stress (blood flow) or the presence of agonists such as bradykinin. Upon stimulation, the cofactor
tetrahydrobiopterin (BH4) is recruited, resulting in the conversion of L-arginine to NO• and L-citrulline. In the vascular lumen, NO• inhibits platelet aggregation and
leukocyte adhesion and migration. NO• produced by endothelial cells diffuses into underlying vascular smooth muscle cells (VSMCs) where it suppresses proliferation
and binds to the ferrous (Fe2+) heme group on its biological target, soluble guanylyl cyclase (sGC). Activation of sGC leads to the production of 3',5'-cyclic guanosine
monophosphate (cGMP) resulting in vasodilation. NO• produced by endothelial cells from coronary vessels, diffuses into cardiomyocytes, where in combination with
NO• produced intracellularly by eNOS and neuronal nitric oxide synthase (nNOS), induces myocardial relaxation, and has anti-hypertrophic effects. NO• also
suppresses thioredoxin-interacting protein (TXNIP) formation in cardiomyocytes and the vasculature.May 2020 | Volume 11 | Article 727
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cardiovascular events.
Nitric Oxide Signaling in the Myocardium
As in the vasculature, NO• plays a key role in the regulation of
heart function. NO•, generated by endothelial cells lining the
coronary vasculature, diffuses into cardiomyocytes where, in
combination with cardiomyocyte nNOS and eNOS-derived
NO•, it has anti-hypertrophic effects, enhances myocardial
relaxation and improves left ventricular diastolic distensibility
(Rosenkranz et al., 2002; Paulus and Bronzwaer, 2004). These
actions of NO• are mediated via sGC/cGMP signaling, and are
cGK-dependent. cGK modulates excitation-contraction coupling
through phosphorylation of troponin I, myosin-binding protein
C and titin, thus decreasing myofilament Ca2+ sensitivity (Farah
et al., 2018). cGK also phosphorylates phospholamban on the
sarcoplasmic reticulum Ca2+-ATPase pump (SERCA2a) pump,
increasing Ca2+ reuptake into the sarcoplasmic reticulum
(Ritchie et al., 2009). Moreover, cGK suppresses L-type
calcium channel activity, further decreasing intracellular Ca2+
levels, which attenuates the positive inotropic effects of beta-
adrenergic signaling, thus promoting cardiomyocyte relaxation
(Massion et al., 2003). cGK also has anti-hypertrophic effects,
due to its ability to regulate Ca2+ current by modulating L-type
Ca2+ channel activity, suppress mitogen-activated protein
kinases, and inhibit myocyte growth and expression of
hypertrophic genes (Ritchie et al., 2009). NO• also modulates
myocardial energetic production through its actions on
mitochondria, where it inhibits mitochondrial respiration and
glucose uptake, and promotes free fatty acid uptake (Massion
et al., 2003; Paulus and Bronzwaer, 2004).IMPAIRED CARDIOVASCULAR NITRIC
OXIDE SIGNALING IN DIABETES
Impaired NO• signaling is present in a wide range of forms of
cardiovascular pathologies and has been documented in obesity,
diabetes, hypertension, atherosclerosis, congestive cardiac
failure, aortic stenosis, angina pectoris, unstable angina,
hyperglycemia/diabetes, myocardial infarction, acute atrial
fibrillation, ageing and polycystic ovarian syndrome (Lees
et al., 1998; Chirkov and Horowitz, 2007; Sverdlov et al., 2014).
In the presence of most coronary risk factors, NO• signaling is
impacted with evidence of a reduction in both synthesis of and
responsiveness to NO• (Worthley et al., 2007; Ito et al., 2015).
Impaired Nitric Oxide Generation
With regard to NO• generation, severe hyperglycemia can lead to
an impairment via reduction of the critical eNOS cofactor BH4,
increased ADMA, eNOS uncoupling, increased arginase activity
and decreased nitrite reduction (Tousoulis et al., 2013; Kövamees
et al., 2016). Reduced BH4 levels have been identified in human
umbilical vein endothelial cells exposed to high glucose
conditions, and in aortae isolated from diabetic mice
(Xu et al., 2007). In this study, hyperglycemia decreased BH4Frontiers in Pharmacology | www.frontiersin.org 4levels via inhibition of 26S proteasome activity of guanosine 5'-
triphosphate cyclohydrolase I (GTPCH), which is a rate-limiting
enzyme of BH4 synthesis, and increased levels of peroxynitrite,
which oxidizes BH4 to dihydrobiopterin (BH2), thereby
uncoupling eNOS (Xu et al., 2007). The authors also found
attenuated endothelium-dependent vasodilation in response to
acetylcholine in aortae from diabetic mice, indicating impaired
vascular generation or responsiveness to NO• per se (Xu et al.,
2007). Similarly, increases in forearm blood flow in response to
acetylcholine, measured by venous occlusion plethysmography,
were impaired in individuals with T2DM, when compared to
non-diabetic controls (Heitzer et al., 2000). Interestingly,
concomitant infusion of BH4 improved forearm blood flow
responses to acetylcholine in T2DM, indicating that the
observed impairment in endothelium-dependent vasodilation,
and hence NO• generation, may be due to decreased BH4
(Heitzer et al., 2000).
NOS competes with arginases and argininemethyltransferases
(PRMT), for its substrate, L-arginine. Arginase converts L-
arginine into L-ornithine or urea, and arginase activity is
elevated in disease states associated with endothelial
dysfunction, including T2DM (Shemyakin et al., 2012;
Kövamees et al., 2016). Similarly, PRMT catalyze the
methylation of L-arginine to monomethylarginine (MMA),
which is converted to ADMA by type 1 PRMT (Zakrzewicz and
Eickelberg, 2009). ADMA is a competitive NOS inhibitor,
reducing NO• generation (Vallance et al., 1992). Indeed,
plasma ADMA levels have been proposed as a clinically
re levant biomarker of endothel ia l dysfunct ion and
cardiovascular disease (Zhou et al., 2017). Thus, a reduction in
endothelium-dependent vasodilation in patients with T2DM,
following ingestion of a high fat meal, has been associated with
increased levels of ADMA (Fard et al., 2000). However,
surprisingly ADMA concentrations are paradoxically lower in
diabetic than non-diabetic patients (Horowitz et al., 2018),
suggesting that NO• generation by NOS activation is not a
major problem in such individuals.
An interesting point for consideration is that endothelial
dysfunction has a component ofNO• resistance that is difficult to
dissect in individual patients byNOS-dependent activation, such
as administration of acetylcholine and salbutamol. Thus, it is
unclear whether the observed “endothelial dysfunction” is
predominantly a reflection of decreased eNOS activity and/or
of impaired ability of NO• to signal per se. This distinction
between “endothelial dysfunction” and isolated NO• resistance
was highlighted in a study by Okon et al., where sensitivity to the
endothelium-dependent vasodilator acetylcholine was 10-fold
lower inmammary arteries from patients with T2DM, compared
to non-diabetic patients, indicating endothelial dysfunction
(Okon et al., 2005). Moreover, eNOS gene and protein
expression was decreased in T2DM mammary arteries by
approximately 50 and 30%, respectively, compared to non-
diabetic counterparts (Okon et al., 2005). However, while this
reduction in vasodilator response to acetylcholine in T2DM
could be due to impaired NO• generation as a consequence of
decreased eNOS expression and activity, the authors also foundMay 2020 | Volume 11 | Article 727
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NO• donor, sodiumnitroprusside (SNP), were also attenuated in
T2DM mammary arteries, indicating reduced vascular
responsiveness to NO•, and hence the presence of NO•
res is tance . Similar ly , brachial-artery flow-mediated
vasodilation was found to be impaired in patients with T2DM
with or without coronary heart disease, when compared to age-
and sex-matched non-diabetic controls (Ito et al., 2015).
However, the authors did not examine endothelium-
independent vasodilation via the use of a NO• donor such as
SNP. Therefore, in this study, it is unclear whether the
impairment in brachial-artery flow mediated vasodilation in
patients with T2DM was due to impaired vascular NO•
generation or signaling or both. This highlights the importance
of testing vascular responsiveness to a NO• donor to delineate
the bases for impaired responses to NOS activators.
Nitric Oxide Resistance
NO• resistance represents a multifaceted disorder, in which
impairments in NO• signaling lead to diminished NO•-
responsiveness in platelets, the vasculature and myocardium,
resulting in a loss in the vaso- and cardio-protective effects of
endogenous and exogenous NO• (Chirkov and Horowitz, 2007).
In patients with cardiovascular disease, the presence of NO•
resistance is an independent predictor of adverse cardiovascular
events and mortality risk (Schachinger et al., 2000; Willoughby
et al., 2012). Several studies have identified NO• resistance in
T2DM (Williams et al., 1996; van Etten et al., 2002; Anderson
et al., 2005; Okon et al., 2005; Shemyakin et al., 2012). In
platelets, the NO• donor SNP inhibited aggregation by 15.4 ±
7% in T2DM, compared to 73.1 ± 5.9% in healthy controls,
indicating decreased platelet responsiveness to NO• in T2DM,
and thus the presence of NO• resistance (Anderson et al., 2005).
In studies by Williams et al., and van Etten et al., patients with
T2DM displayed vascular NO• resistance, indicated by reduced
brachial artery flow-mediated vasodilation in response to SNP,
compared to healthy controls (Williams et al., 1996; van Etten
et al., 2002). Similarly, vasodilator response of the brachial artery
in response to intra-arterial infusion of SNP was lower in
patients with coronary artery disease and T2DM, compared to
healthy controls, indicating decreased VSMC responsiveness to
NO•, and thus NO• resistance (Shemyakin et al., 2012). To the
best of our knowledge, the presence of myocardial NO•
resistance has not thus far been examined in T2DM. However,
in a rat model of T1DM, both myocardial contractile and
relaxation responses to the NO• donor diethylamine-NONOate
(DEA/NO) were impaired, establishing the presence of
myocardial NO• resistance in T1DM (Qin et al., 2020). Thus,
it is probable that NO• resistance also occurs at the level of the
human myocardium in T2DM, particularly as platelet and
vascular responsiveness to NO• is diminished in these patients.
Although the pathogenesis of T2DM is different to that of
T1DM, they are both characterized by hyperglycemia, and
associated with oxidative stress, both of which can contribute
to impairment of NO• signaling (Fiorentino et al., 2013).Frontiers in Pharmacology | www.frontiersin.org 5OXIDATIVE STRESS AS A CONTRIBUTOR
TO NITRIC OXIDE RESISTANCE
NO• resistance occurs largely due to oxidative stress, where ROS
scavenge NO• and reversibly inactivate sGC, resulting in
impaired tissue responsiveness to endogenous or exogenous
NO• (Dautov et al., 2013; Tare et al., 2017). Oxidative stress
refers to an imbalance between the generation of ROS and their
clearance by endogenous antioxidants, such as superoxide
dismutase, catalase and glutathione peroxidase (Wink et al.,
2001). ROS consist of free-radical species, including
superoxide, peroxyl, hydroxyl and hydroperoxyl, and non-
radicals, such as hydrogen peroxide, peroxynitrite and
hypochlorous acid (Phaniendra et al., 2015). They are
generated by the mitochondrial electron transport chain, in
addition to several other sources including xanthine oxidase,
NADPH oxidases, iNOS, and uncoupled eNOS (Brownlee, 2005;
Pignatelli et al., 2018).
ROS have a marked impact on NO• generation and signaling.
Specifically, NO• reacts rapidly with superoxide forming the
powerful oxidant peroxynitrite, which reduces the bioavailability
of NO• (Ritchie et al., 2017). In Langendorff-perfused rat hearts,
superoxide directly quenches NO•, reducing basal- and agonist-
induced NO• release and subsequent vasodilation of the
coronary vasculature, in the absence of modifications in eNOS
expression or activity (Paolocci et al., 2001a). Peroxynitrite
uncouples eNOS by oxidizing BH4 to BH2, which leads to
electron donation to molecular oxygen (O2), resulting in the
generation of superoxide, further exacerbating oxidative stress
(Farah et al., 2018). In addition, peroxynitrite is able to oxidize
the ferrous (Fe2+) heme group on sGC to its ferric (Fe3+) state,
desensitizing the enzyme to NO•. Furthermore, oxidation of the
heme group weakens its binding, resulting in a heme-free form of
sGC which is susceptible to ubiquitin-dependent degradation
(Meurer et al., 2009). Consequently, tissue responsiveness to
endogenous and exogenous NO• is impaired, resulting in NO•
resistance (Ritchie et al., 2017) (Figure 3).
Hyperglycemia-Induced Oxidative Stress
In T2DM, hyperglycemia can lead to oxidative stress via
increased NADPH oxidase activity, overproduction of
mitochondrial ROS and elevated expression of TXNIP
(Figure 2) (Aon et al., 2015). Elevated myocardial NADPH
oxidase-derived superoxide production has been identified in a
mouse model of T2DM, and was found to exacerbate left
ventricular remodeling and heart failure post-myocardial
infarction, when compared to non-diabetic controls
(Matsushima et al., 2009). Moreover, internal mammary
arteries from patients with T2DM undergoing coronary bypass
surgery, displayed elevated NADPH oxidase-derived superoxide
levels, and increased membrane translocation of the Nox1/2
regulatory subunits p47phox and Rac1 (Antonopoulos et al.,
2015). Nox1 and Nox2 are the major sources of ROS in the
vascular wall (Drummond et al., 2011). Therefore, increased
membrane translocation of their regulatory subunits p47phox andMay 2020 | Volume 11 | Article 727
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vasculature in T2DM.
Hyperglycemia can also stimulate overproduction of
mitochondrial ROS, as higher levels of intracellular glucose-
derived pyruvate increase flux of electron donors NADH and
FADH2 into the electron transport chain (Giacco and Brownlee,
2010). This increases the voltage gradient across the
mitochondrial membrane, preventing electron transfer within
complex III (Giacco and Brownlee, 2010). Consequently,
electrons accumulate at coenzyme Q10, which donates
electrons to molecular oxygen, resulting in superoxide
generation, which combined with superoxide generated from
other sources such as NADPH oxidase, causes DNA strand
breaks (Pacher and Szabó, 2005; Giacco and Brownlee, 2010).
This results in activation of poly (ADP-ribose) polymerase
(PARP), an enzyme involved in DNA repair, which under
normal conditions, resides within the nucleus in an inactive
state (Brownlee, 2005). Once activated, PARP modifies the
glycolytic enzyme glyceraldehyde-3 phosphate dehydrogenase
(GAPDH), reducing its activity (Brownlee, 2005). Decreased
GAPDH activity leads to overactivation of the hexosamine
pathway, upregulation of protein kinase C (PKC), elevated
glucose flux through the polyol pathway and increased
formation of advanced glycation end-products (AGEs), all of
which can promote impairments in NO• generation and/or
signaling (Fiorentino et al., 2013) (Figure 2).Frontiers in Pharmacology | www.frontiersin.org 6Hexosamine Pathway
In the hexosamine pathway, O-GlcNAc transferase (OGT)
catalyzes a post-translational modification, known as O-
GlcNAcylation, of proteins modulating their biological activity
(Qin et al., 2017). Increased O-GlcNAcylation has been
identified in patients with T2DM (Degrell et al., 2009;
Springhorn et al., 2012). Overactivation of this pathway can
lead to elevated endothelial expression of the pro-inflammatory
and pro-atherogenic mediators VCAM-1, ICAM-1 and
plasminogen activator inhibitor-1 (PAI-1) (Fiorentino et al.,
2013) (Figure 2). A recent study identified decreased NO•
production, reduced eNOS expression, and increased O-
GlcNAcylation of eNOS in perivascular adipose tissue from
thoracic aortae from rats with metabolic syndrome (da Costa
et al., 2018). As a result, the anti-contractile capacity of the
perivascular adipose tissue was diminished (da Costa et al.,
2018). Moreover, increased O-GlcNAcylation of myocardial
proteins has been associated with cardiac dysfunction in mouse
models of T2DM (Fülöp et al., 2007; Marsh et al., 2011).
Protein Kinase C
PKC consists of a family of serine/threonine kinases, which play an
important role in signal transduction of several vascular functions,
including regulation of angiogenesis, endothelial cell permeability,
extracellular matrix deposition and vasoconstriction (Kizub et al.,
2014). In a study by Tabit et al., in patients with T2DM, endothelialFIGURE 2 | Hyperglycemia-induced oxidative stress impairs nitric oxide signaling. Hyperglycemia induces oxidative stress via increased activity of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase (Nox) enzymes including Nox2, resulting in superoxide (O2
−) generation. In mitochondria, hyperglycemia increases
reactive oxygen species (ROS) production including O2
−, which stimulates thioredoxin-interacting protein (TXNIP) expression. TXNIP promotes activation of the
NLRP3 inflammasome, which activates caspase-1, resulting in the maturation and secretion of the pro-inflammatory cytokines, interleukin-1b (IL-1b) and interleukin-
18 (IL-18). O2
− also causes strand breaks in DNA, leading to activation of poly (ADP-ribose) polymerase (PARP), which reduces activity of glyceraldehyde-3
phosphate dehydrogenase (GAPDH). Decreased GAPDH activity leads to overactivation of the hexosamine pathway, upregulation of protein kinase C (PKC), elevated
glucose flux through the polyol pathway and increased formation of advanced glycation end-products (AGEs). This leads to activation of Nox and NF-kB signaling,
resulting in increased expression of pro-inflammatory and pro-atherogenic mediators including vascular adhesion molecule-1 (VCAM-1), intracellular adhesion
molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), plasminogen activator inhibitor-1 (PAI-1) and interleukin-6 (IL-6). Upregulation of these pathways
results in impaired flow-mediated vasodilation, reflecting both endothelial dysfunction and nitric oxide (NO•) resistance.May 2020 | Volume 11 | Article 727
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flow-mediateddilationof the brachial artery (Tabit et al., 2013).The
authors also found increased endothelial levels of the peroxynitrite
derivative nitrotyrosine, and elevated activity of NF-kB, indicating
the presence of endothelial inflammation and nitrosative/oxidative
stress in T2DM (Tabit et al., 2013).
The Polyol Pathway
In the polyol pathway, glucose is reduced to sorbitol by aldose
reductase, which consumes NADPH in the process (Chandra
et al., 2002). NADPH consumption limits NO• production and
exacerbates oxidative stress, as NADPH is required for the
production of NO• and the antioxidant reduced glutathione
(Ramana et al., 2003; Lorenzi, 2007). The deleterious effects of
sorbitol on the microvasculature have been demonstrated in rat
gracilis arterioles, where exposure to sorbitol stimulated vascular
production of ROS, and impaired endothelium-dependent and
endothelium-independent vasodilation to a NO• donor,
indicating that sorbitol can induce endothelial dysfunction
with a substantial component of NO• resistance (Toth et al.,
2007) (Figure 2). In addition, methylglyoxal, an intermediate of
this pathway, is implicated in endothelial dysfunction and
elevated in patients with T2DM (Wang et al., 2007; Lund et al.,
2011). Methylglyoxal is also a potent glycating agent that reacts
with intracellular and extracellular proteins, resulting in the
formation of AGEs (Lund et al., 2011).
Advanced Glycation End-Products
AGEs are formed during non-enzymatic reactions between
reducing sugars or sugar-derived products and amino groups
on proteins, lipids or nucleic acids (Barlovic et al., 2010). AGEs
and their receptor (receptor for AGEs; RAGE) play a central role
in the pathogenesis of vascular complications (Thomas et al., 2005).
In patients with T2DM, plasma levels of AGEs are elevated, and
negatively correlated with endothelium-dependent and
endothelium-independent vasodilation (Tan et al., 2002).
Moreover, plasma levels of AGEs are approximately 74% higher
in patients with T2DM with vascular complications, compared to
those with T2DM without vascular complications (Farhan and
Hussain, 2019). Activation of RAGE by AGEs also stimulates
NADPH oxidase, increasing intracellular ROS generation,
subsequently activating NF-kB, resulting in the production of
pro-inflammatory and pro-atherogenic mediators, including IL-6,
VCAM-1, ICAM-1 and MCP-1 (Barlovic et al., 2010) (Figure 2).
Consequently, oxidative stress and inflammation are exacerbated,
leading to further impairments in NO• signaling (Andrews et al.,
2016). NF-kB activation also stimulates NO• generation by iNOS,
however, when superoxide levels are elevated, superoxide anions
react with NO• forming peroxynitrite (Wright et al., 2006). This
leads to a loss of the inhibitory effects of iNOS-derivedNO• onmast
cell stabilization (Coleman, 2002),which is critical for preventionof
plaque rupture and coronary vasospasm, which precede most
ischemic emergencies (Kovanen et al., 1995; Laine et al., 1999).
Thioredoxin-Interacting Protein (TXNIP)
Hyperglycemia is also associated with increased expression of
TXNIP via the glucose-response element in its geneFrontiers in Pharmacology | www.frontiersin.org 7(Turturro et al., 2007). Thioredoxin (TRX) is a key modulator of
intracellular redox stress, possessing antioxidant activity. TXNIP
serves as a negative regulator of TRX and contributes to oxidative
stress indiabetes, in addition to promoting inflammationwith a key
role inNLRP3 inflammasome activation (Schulze et al., 2004; Zhou
et al., 2010) (Figure 2). TXNIP gene expression is elevated in
peripheral bone mononuclear cells from patients with T2DM,
compared to patients with T1DM and non-diabetic controls
(Szpigel et al., 2018). This increase in TXNIP was accompanied
by elevated gene expression of NLRP3 and IL-1b, indicating that
TXNIP promotes inflammation inT2DM through activation of the
NLRP3 inflammasome (Szpigel et al., 2018). These actions of
TXNIP are likely to negatively impact NO• signaling in T2DM.
Indeed, a reciprocal relationship between platelet NO•
responsiveness and TXNIP expression has been demonstrated
(Sverdlov et al., 2013).
Collectively, these data provide robust evidence for a key role
of oxidative stress and inflammation in the development of
cardiovascular complications in T2DM. Central to the disease
pathology is an impairment in endogenous and exogenous NO•
signaling. Taking into consideration the more prominent role of
NO• resistance in impaired NO• signaling in diabetes, there is a
strong therapeutic focus on overcoming NO• resistance in this
disease setting.CURRENT AND EMERGING
PHARMACOTHERAPIES TO OVERCOME
IMPAIRED NITRIC OXIDE SIGNALING:
A FOCUS ON NITRIC OXIDE RESISTANCE
Ashighlighted,NO• resistance is particularly debilitating inT2DM,
where themortality risk associatedwith cardiovascular emergencies
is increased (e.g. acute myocardial infarction, transient myocardial
ischemia, acute pulmonary edema) (Lindholm et al., 2005). In these
circumstances, rapid vasodilator and anti-aggregatory actions are
required yet NO•-based pharmacotherapies are ineffective. Thus,
whilst nitrovasodilators, including the organic nitrate glyceryl
trinitrate (GTN), have been clinically utilized since 1876 for the
treatmentof anginapectoris andheart failure (Sun et al., 2011), their
effectiveness is diminished in the very conditions for which they are
most needed. As such, NO•-independent therapeutic approaches
aimed at ameliorating or circumventing NO• resistance,
particularly to manage cardiovascular emergencies, are urgently
required for the diabetic population.
Amelioration Strategies
A number of treatments, including some ACE inhibitors,
perhexiline, statins, and reversal of severe hyperglycemia have
been shown to ameliorate NO• resistance (Table 1).
ACE Inhibitors
Increased activity of the renin-angiotensin system and the
generation of angiotensin II, which possesses pro-oxidative,
pro-inflammatory and vasoconstrictive properties, is associated
with many cardiovascular diseases (Ruszkowski et al., 2019). The
ACE inhibitors ramipril and perindopril decrease the formationMay 2020 | Volume 11 | Article 727
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Outcomes Prevention Evaluation; EUROPA, European Trial
on Reduction of Cardiac Events with Perindopril), have been
shown to reduce the incidence of myocardial infarction, cardiac
arrest, heart failure, stroke and diabetes-related complications in
aging, high-risk adults with vascular disease or diabetes (Yusuf
et al., 2000; Fox, 2003).
Whilst the precise mechanisms underlying the improved
cardiovascular outcomes following treatment with ramipril or
perindopril remain unclear, an ability of these ACE inhibitors to
ameliorate NO• resistance may contribute to treatment benefit.
Ramipril and perindopril have been shown to improve NO• donor
responsiveness, at least at the level of the platelet. In individualswith
chronic heart failure, treatment with perindopril for 4 days
improved platelet responsiveness to SNP, reducing the proportion
of subjects with platelet NO• resistance from 40 to 0% (Chirkov
et al., 2004). Similarly, the effect of ramipril on platelet
responsiveness to SNP was assessed in a randomized, placebo-
controlled, blinded study in older adults (aged ≥50 years) of high
cardiovascular risk (history of stroke, coronary artery disease,
peripheral vascular disease and/or diabetes) (Willoughby et al.,
2012). In this study, 3months of ramipril therapydecreased systolic
and diastolic pressure, and reduced augmentation index (Aix) and
plasma levels ofADMA,markers of arterial stiffness andendothelial
dysfunction, respectively (Willoughbyet al., 2012).The authors also
identified a separate group of participants with diabetes, who
displayed severe platelet NO• resistance at baseline, in which
ramipril therapy for 2 weeks improved platelet responsiveness to
SNP, suggesting improved sensitivity of sGC to NO• (Willoughby
et al., 2012).
Based on these findings, it is clear that long-term therapy with
the ACE inhibitors ramipril or perindopril overcomes NO•
resistance and provides protection against adverse cardiovascular
events in high-risk populations. However, ACE inhibitor-mediated
reversal of NO• resistance is not an option for patients who are
intolerant of ACE inhibition, many of whom are diabetic (Neutel,
2010; DuMond and King, 2011). Moreover, the use of ACE
inhibitors to attenuate NO• resistance in a cardiovascular
emergency is clinically impracticable with the CONSENSUS II
study (Cooperative New Scandinavian Enalapril Survival Study II)
showing that the intravenous administration of the ACE inhibitor,
enalaprilat, within 24 h of an acute myocardial infarct, increased
mortality (Swedberg et al., 1992).
Perhexiline
The anti-anginal agent, perhexiline, has shown some promise
with regard to ameliorating NO• resistance. Used in patients
refractory to commonly used antianginal therapies, the anti-
ischemic properties of perhexiline are attributed to its ability to
inhibit the mitochondrial enzyme carnitine palmitoyltransferase,
leading to the reduction in fatty acid metabolism and a shift to
greater carbohydrate metabolism by the myocardium (oxygen
sparing effect) (Ashrafian et al., 2007). In addition, perhexiline
limits oxidative stress via inhibition of NADPH oxidase
(Kennedy et al., 2006). Studies have demonstrated an ability of
perhexiline to improve platelet SNP responsiveness in patients
with stable angina pectoris (Chirkov et al., 2001), acute coronaryFrontiers in Pharmacology | www.frontiersin.org 8syndromes (Willoughby et al., 2002) and aortic stenosis (Chirkov
et al., 2002). However, the clinical utility of perhexiline is limited
due to its complex pharmacokinetics and potential to cause
hepatic- and neuro-toxicity, necessitating close therapeutic
monitoring (Chong et al., 2016).
Statins
Statins are lipid-lowering drugs that are primarily used to treat
hypercholesterolemia and prevent the progression of
cardiovascular disease (Ko et al., 2019). Whilst statin therapy is
associated with improvement in endothelial function in patients
with cardiovascular disease (Reriani et al., 2011), evidence in
support of an ability of statins to ameliorate vascular NO•
resistance is conflicting. Thus, in patients with T1DM,
atorvastatin (40 mg/day; 6 weeks) was shown to improve
nitroglycerin-mediated dilatation in the brachial artery (Dogra
et al., 2005). Similarly, following an acute coronary syndrome,
atorvastatin treatment (80 mg/day, 16 weeks) lead to an
improvement in GTN-mediated dilation (Dupuis et al., 2005).
By contrast, atorvastatin (40 mg/day; 6 weeks) therapy in
patients with non-ischemic chronic heart failure, did not lead
to an improvement in GTN-mediated dilation in the brachial
artery (Strey et al., 2006). At the level of the platelet there is data,
albeit limited, to suggest that statin therapy ameliorates NO•
resistance. For example, in patients with acute coronary
syndrome, pharmacotherapy with statins was associated with
improved anti-aggregatory actions of SNP (Chirkov et al., 2001).
In addition, in individuals with mild hypercholesterolemia,
treatment with pravastatin (40 mg/day) for 3 months,
improved inhibition of platelet aggregation in response to SNP
(Stepien et al., 2003). Of note, the ability of statins to ameliorate
NO• resistance is unlikely due to their cholesterol lowering
actions per se, rather their pleiotropic effects such as an ability
to reduce superoxide generation and oxidative stress may be
responsible. However, acute introduction of statins during
evolving acute myocardial infarction has not convincingly
improved outcomes (Ostadal, 2012; Vavuranakis et al., 2017).
Reversal of Severe Hyperglycemia
As discussed, hyperglycemia is a key contributor to the endothelial
dysfunction and macrovascular complications associated with
diabetes. Moreover, hyperglycemia contributes to vascular NO•
resistance, such that glucose lowering, with long-term insulin
treatment (3.5 years), improves brachial artery vasodilatation to
SNP in patients with T2DM (Vehkavaara and Yki-Järvinen, 2004).
Similarly, in diabetic patients with severe hyperglycemia and acute
coronary syndromes, rapid correction of hyperglycemia via
intravenous insulin (12 h) increases platelet responsiveness to
NO• (Worthley et al., 2007). Such protective actions of insulin are
likely due to its ability to reduce oxidative stress, independently of
the potential for acute modulation of platelet TXNIP expression
(Chong et al., 2015). Indeed, in the DIGAMI study (Diabetes
Mellitus Insulin-Glucose Infusion in Acute Myocardial
Infarction), insulin infusion post-acute myocardial infarction,
followed by multi-dose subcutaneous insulin administration,
decreased mortality rate in patients with diabetes (Malmberg
et al., 1995). These findings suggest that the relatively rapid effectsMay 2020 | Volume 11 | Article 727
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patients experiencing acute myocardial infarction, however, it
should be noted that a component of NO• resistance may persist
following acute, aggressive glycemic control (12 h insulin i.v.
infusion) (Worthley et al., 2007).
Whilst the pharmacotherapies discussed have the potential to
ameliorateNO• resistance at the level of the vasculatureandplatelet,
all of these strategies have delayed onset of activity, taking hours to
days to take effect. As such they are unsuitable for emergency
situations (e.g. acute MI, transient myocardial ischemia or acute
pulmonary edema), in which rapid circumvention of NO•
resistance is required. This is of particular relevance in the
diabetic population in which cardiovascular emergencies occur
with greater frequency.Circumvention Strategies
Emerging therapeutic strategies to circumvent NO• resistance,
include sGC activators, nitrite and HNO donors (Table 1).
sGC Activators
Since NO• resistance is associated with sGC oxidation to the
NO•-insensitive Fe3+-sGC and subsequent heme-deplete sGC
forms, the use of NO•- and heme-independent sGC activators to
overcome this limitation has gained considerable attention. sGCFrontiers in Pharmacology | www.frontiersin.org 9activators target sGC in its oxidized (Fe3+) or heme-free states
and as such have greater efficacy under conditions of oxidative
stress (Sandner et al., 2019). Pre-clinical studies have identified
protective effects of sGC activators against ischemia/reperfusion
injury, myocardial infarction, diabetic cardiomyopathy and
diabetic nephropathy (Mátyás et al., 2015; Boustany-Kari et al.,
2016; Lee et al., 2017). Furthermore, sGC activatorsmay ameliorate
NO• resistance. Thus, chronic treatment of rats with heart failure
with the sGC activator, ataciguat (10 mg/kg/twice daily, 10 weeks)
improved the vascular response to exogenous NO• in aortic rings
and reduced platelet activation (Schäfer et al., 2010). Importantly,
sGC activators themselves are anti-aggregatory agents and their
anti-platelet actions in both humans (Mendes-Silverio et al., 2012)
and rodents (Roger et al., 2010) are augmented when sGC is
oxidized. Such findings suggest that sGC activators have the
potential to circumvent NO• resistance. Currently, however, the
clinical utility of this class of compound is unclear given their
profound, and sustained, blood pressure lowering effects in patients
with acute decompensated heart failure (Breitenstein et al., 2017)
andperipheral arterial occlusive disease (Sandner et al., 2019), in the
absence of a clear therapeutic benefit.
Nitrite
There is growing interest in the therapeutic potential of nitrite,
both as an alternate source of NO• and a signaling molecule in itsTABLE 1 | Current and emerging therapies to ameliorate and circumvent nitric oxide resistance.





•Decrease angiotensin II formation
•Improve endothelial function by
decreasing bradykinin degradation
•Benefits observed following prolonged
use (days to months)
•Limited utility during cardiovascular
emergencies
(Murphey et al., 2003; Chirkov et al., 2004; Lob et al.,
2006; Willoughby et al., 2012)
Perhexiline •Anti-ischemic
•Inhibits mitochondrial enzyme carnitine
palmitoyltransferase
•Potential neuro- & hepato-toxicity
•Variable pharmacokinetics: close
therapeutic monitoring required
(Ashrafian et al., 2007; Chong et al., 2016)
Statins •Lower cholesterol
•Increase hepatic LDL uptake
•Enhance eNOS gene expression
•Enhance eNOS activity by reducing
caveolin-1 expression
•Benefits observed following prolonged
use (days to months)
•Limited utility during cardiovascular
emergencies
(Willoughby et al., 2002; Stepien et al., 2003; Chirkov






•Reduce oxidative stress and
superoxide production
•NO• resistance can persist following
acute, aggressive glycaemic control
•Beneficial effects on mortality unclear
(Vehkavaara and Yki-Järvinen, 2004; Mehta et al., 2005;
Worthley et al., 2007)
Circumvention strategies
sGC activators •Bind to heme pocket of sGC
•Heme-independent
•Activate sGC if heme is oxidized or
detached
•Can cause hypotension (Follmann et al., 2013; Buys et al., 2018; Elgert et al.,
2019)
Nitrite •Converted to NO• via reductases
•Vasodilator & anti-aggregatory actions
potentiated in hypoxia
•Anti-platelet effect diminished in
patients with IHD
•Does not reduce infarct size post-acute
myocardial infarction
(Dautov et al., 2013; Siddiqi et al., 2014; Jones et al.,
2015)




•Resistant to oxidative stress
•May cause coronary steal
•Long-term benefits remain to be
elucidated
(Irvine et al., 2007; Kemp-Harper, 2011; Dautov et al.,
2013)May 2020 | Volume 11 | Article 727
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responses to nitrite are potentiated in the setting of hypoxia,
suggesting that it may have considerable advantages in the
treatment of acute cardiovascular disorders (Dautov et al.,
2014). However, current evidence in support of an ability of
nitrite to circumvent NO• resistance is limited, and hinges on the
concept that part of the effects of nitrite are NO•- and sGC-
independent. Thus, in platelets from patients with ischemic heart
disease, in whom NO• resistance is evident, the anti-aggregatory
effects of nitrite were found also to be diminished (Dautov et al.,
2014). By contrast, in heart failure patients with preserved
ejection fraction (HFpEF), resistance to the anti-aggregatory
actions of SNP was evident, yet the ability of nitrite to inhibit
platelet aggregation was maintained (Borgognone et al., 2018).
Whilst these anti-aggregatory actions of nitrite were mediated via
sGC activation, they were only due, in part, to NO•. The clinical
utility of nitrite in the circumvention of NO• resistance is also
tempered by the finding that in two clinical trials in patients with
acute myocardial infarction (NIAMI and NITRITE-AMI), nitrite
administration prior to reperfusion, did not reduce infarct size
(Siddiqi et al., 2014; Jones et al., 2015).
Nitroxyl-Based Therapies
HNO is the one-electron reduced and protonated form of NO•.
Using the prototypical HNO donors Angeli's salt (which is also a
source of nitrite) and iso-propylamine-NONOate (IPA-NO),
HNO has been shown to have distinct pharmacological
properties and therapeutic advantages when compared to its
redox sibling (Irvine et al., 2008; Bullen et al., 2011a). Specifically,
unlike NO•, the actions of HNO are preserved during oxidative
stress, as HNO is resistant to scavenging by superoxide (Irvine
et al., 2007; Kemp-Harper et al., 2016). Moreover, HNO causes
venous and arterial dilation (Tare et al., 2017), suppresses
vascular generation of ROS via rapid (within minutes), and
direct, inhibition of Nox2 oxidase (Miller et al., 2013) and is
resistant to tolerance development (unlike organic nitrates)
(Irvine et al., 2007). HNO also inhibits VSMC proliferation
and platelet aggregation (Tsihlis et al., 2010; Bullen et al.,
2011b; Dautov et al., 2013), and reduces endothelial expression
of adhesion molecules, monocyte activation and leukocyte
adhesion (Andrews et al., 2016). In the vasculature, HNO
induces vasodilation predominantly through sGC/cGMP
signaling and the preference of HNO for ferric (Fe3+) versus
ferrous (Fe2+) heme groups (Miranda et al., 2003) raises the
interesting possibility that HNO may preferentially target the
oxidized (Fe3+) versus reduced (Fe2+) forms of sGC. Such a
property may contribute to the preserved efficacy of HNO in the
face of oxidative stress, yet studies to date have not provided
evidence in support of an ability of HNO to activate oxidized
sGC (Miller et al., 2009; Zeller et al., 2009). In comparison to
NO•, HNO can also signal via distinct vascular pathways,
including the activation of voltage-dependent K+ channels
(Irvine et al., 2003; Andrews et al., 2009), ATP-sensitive K+
channels and the release of calcitonin gene-related peptide
(Figure 3) (Favaloro and Kemp-Harper, 2007; Chin et al.,
2014). Interestingly, HNO might also be endogenouslyFrontiers in Pharmacology | www.frontiersin.org 10generated, however, in the absence of a validated method to
measure tissue levels, this is yet to be established conclusively
(Andrews et al., 2009; Kahlberg et al., 2016; Fukuto, 2019).
Another unique feature of HNO in comparison to NO•, is the
ability of HNO to react directly with thiols and thiol-containing
proteins (i.e. cysteines), independently of sGC/cGMP signaling
(Kemp-Harper, 2011). In the myocardium, this property allows
HNO to serve as a positive cardiac inotrope, interacting with
cysteine residues on thiol-containing proteins including
ryanodine receptors (Tocchet t i e t a l . , 2007) and
phospholamban, the regulatory phosphoprotein of the
sarcoplasmic reticulum Ca2+-ATPase pump (SERCA2a), to
enhance Ca2+ cycling (Keceli et al., 2019). HNO also increases
myofilament calcium sensitivity by promoting the formation of
disulfide bonds between myofilament cysteine residues (Gao
et al., 2012), Together, these actions of HNO result in
enhanced myocardial contractility and relaxation (Figure 3)
(Paolocci et al., 2007; Tocchetti et al., 2007). It should also be
noted that differently from legacy inotropes, the inotropic
response to HNO does not require the entry of extracellular
Ca2+ (Kohr et al., 2010).
These unique properties of HNO, together with its preserved
efficacy in the setting of oxidative stress, suggest that HNO
donors may circumvent NO• resistance and be of clinical
utility in a cardiovascular emergency.
Indeed, HNO donor compounds have displayed vaso- and
cardio-protective efficacy, particularly in disease states where
endothelial dysfunction and NO• resistance is present (Andrews
et al., 2016). At the level of the vasculature, there is evidence to
support an ability of both endogenous and exogenous HNO to
circumvent NO• resistance. Thus, in the diabetic rat aorta (Leo
et al., 2012) and small mesenteric arteries (Kahlberg et al., 2016;
Tare et al., 2017), endothelium-dependent relaxation mediated
by HNO is preserved, yet that mediated by NO• is impaired.
Moreover, in pre-clinical studies, vasorelaxation to the HNO
donors, Angeli's salt and IPA/NO are maintained in the diabetic
(Leo et al., 2012; Tare et al., 2017), hypercholesterolemic (Bullen
et al., 2011b) and hypertensive (Wynne et al., 2012; Irvine et al.,
2013) vasculature. Importantly, HNO can also circumvent
platelet NO• resistance. Thus, in hypercholesterolemic mice we
have shown that the anti-aggregatory actions of the HNO donor,
IPA/NO are preserved, yet those to the NO• donor, GTN are
impaired (Bullen et al., 2011b). Moreover, in patients with
coronary artery disease, the impaired anti-platelet response to
the NO• donor, SNP, is circumvented by the HNO donor, IPA/
NO (Dautov et al., 2013).
Whilst the discussion so far has focused on circumventing NO•
resistance in the vasculature and platelets, it is pertinent to note that
the myocardium is also susceptible to NO• resistance, such that
NO• can no longer enhance left ventricular (LV) relaxation (Qin
et al., 2020). Thus, following ischemia–reperfusion (I–R) injury
(Chin et al., 2016) or the induction of T1DM (Qin et al., 2020) in
rats, the ability of the NO• donor, DEA/NO to enhancemyocardial
relaxation is impaired. Such an impairment in myocardial
responsiveness to NO• (endogenous or exogenous) may facilitate
LV dysfunction, LV hypertrophy and cardiac remodellingMay 2020 | Volume 11 | Article 727
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studies have demonstrated that HNO donors can circumvent
myocardial NO• resistance. Specifically, unlike DEA/NO,
myocardial relaxation to Angeli's salt is preserved following I–R
injury in rat isolated hearts (Chin et al., 2016). In addition, Angeli's
salt was found to reduce the duration of ventricular fibrillation
following I–R injury (Chin et al., 2016). Similarly, the HNO donor
IPA/NO enhanced myocardial relaxation and contraction
responses in diabetic rat hearts, while responses to DEA/NO were
attenuated (Qin et al., 2020).
Collectively these findings suggest that HNO donors may be
particularly useful in acute cardiovascular emergencies
associated with NO• resistance. Indeed, the ability of HNO to
rapidly unload the heart (venous dilation) (Paolocci et al.,
2001b), improve coronary blood flow (arterial dilation)
(Paolocci et al., 2003; Andrews et al., 2015) and inhibit platelet
aggregation (Bermejo et al., 2005; Bullen et al., 2011b; Dautov
et al., 2013) is highly advantageous following an ischemic event.
Moreover, the positive inotropic and lusitropic properties of
HNO (Paolocci et al., 2003; Sabbah et al., 2013) provide a unique
therapeutic approach in which an improvement in myocardial
performance can also be achieved in this setting. Future studies
should also determine if HNO donors have the ability to stabilize
mast cells and if this action is preserved in the face of impaired
NO• signaling. Indeed, mast cell stabilization is critical for the
prevention of plaque rupture and coronary spasm, events whichFrontiers in Pharmacology | www.frontiersin.org 11trigger most cardiac ischemic emergencies (Kovanen and Bot,
2017). A caveat of many nitrovasodilators is the coronary steal
phenomenon, where non-specific vasodilators induce dilation in
non-ischemic regions and reduce systemic blood pressure,
causing blood flow to be directed away from ischemic regions
of need (Harrison and Bates, 1993). Whilst there is no current
evidence that HNO donors cause coronary steal, this concept has
not been fully interrogated and whether HNO selectivity targets
ischemic sites remains unknown. With the recent development
of the next-generation HNO donors and their ongoing clinical
evaluation, these concepts will need to be investigated.
To date, the therapeutic benefits of short-term HNO
administration has been a key focus. However, many of the
properties of HNO confer potential for long-term use in the
treatment of cardiovascular pathologies associated with impaired
NO• signaling. Thus in addition to the vasodilatory, anti-
aggregatory and inotropic actions of HNO donors, their ability
to attenuate oxidative stress (Lin et al., 2012; Miller et al., 2013),
inflammation (Andrews et al., 2016) and cardiac hypertrophy (Lin
et al., 2012; Irvine et al., 2013) and their resistance to tolerance
development (Irvine et al., 2011; Andrews et al., 2015) is
advantageous. Indeed, the long-term cardioprotective actions of
HNO in the diabetic heart is supported by our finding that chronic
in vivo administration of the HNO donor, 1-nitrosocyclohexyl
acetate (1-NCA, daily i.p. injection for 4 weeks) to streptozotocin-
treated mice, attenuated left ventricular diastolic dysfunction andFIGURE 3 | Nitric oxide resistance and its circumvention by nitroxyl. Under oxidative stress, activity of nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase (Nox) enzymes, such as Nox2, is elevated, resulting in increased superoxide (O2
−) generation. O2
− reacts with nitric oxide (NO•), generating the powerful
oxidant, peroxynitrite (ONOO-), which oxidizes the ferrous (Fe2+) heme group of sGC to the ferric (Fe3+) or heme-free state, desensitizing the enzyme to NO•.
Consequently, tissue responsiveness to NO• is impaired, resulting in NO• resistance. Nitroxyl (HNO) is resistant to scavenging by O2
− and HNO donors offer an
opportunity to circumvent NO• resistance. In the vasculature, HNO causes vasorelaxation, inhibits platelet aggregation and reduces monocyte activation. In vascular
smooth muscle cells (VSMCs), HNO signals predominantly via activation of sGC and the subsequent increase in 3',5'-cyclic guanosine monophosphate (cGMP) and
may activate the oxidized (Fe3+) form of sGC. HNO also targets vascular voltage-dependent and ATP-sensitive K+ channels through a cGMP-dependent mechanism.
In the vasculature and myocardium, HNO interacts directly with Nox2 to suppresses O2
- generation. In cardiomyocytes, HNO has anti-hypertrophic effects, and
reacts directly with thiols and thiol-containing proteins including the sarcoplasmic reticulum Ca2+-ATPase pump (SERCA2a) and ryanodine receptors (RyR2) to
enhance Ca2+ cycling, together with increasing myofilament Ca2+ sensitivity, resulting in enhanced myocardial contractility and relaxation. The vaso- and cardio-
protective actions of HNO are preserved in the setting of oxidative stress and HNO donors offer a new therapeutic approach to treat diabetes-associated
cardiovascular complications.May 2020 | Volume 11 | Article 727
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development of HNO donors with more favorable
pharmacokinetic properties (del Rio et al., 2014; Hartman et al.,
2018), it is anticipated that the therapeutic potential of this class of
compound in the treatment of both acute and chronic
cardiovascular diseases will be rigorously investigated.
Next-Generation Nitroxyl Donors
Given the short half-life, poor aqueous solubility and active by-
products released by the abovementioned HNO donors, novel
synthetic pure HNO donors have now been developed. These
include CXL-1020, which non-enzymatically decomposes to
HNO with a half-life of approximately 2.1 min (Sabbah et al.,
2013). CXL-1020 has been shown to induce positive inotropic
and lusitropic effects in murine cardiomyocytes from healthy or
failing hearts, and these effects were also observed in vivo in
failing canine hearts (Sabbah et al., 2013). In patients with acute
decompensated heart failure, intravenous infusion (4–6 h) of
CXL-1020 enhanced cardiac function by reducing left and right
ventricular pressures, decreasing systemic vascular resistance,
and increasing cardiac output and stroke volume (Sabbah et al.,
2013). These hemodynamic changes were not associated with
alterations in heart rate, or the occurrence of arrhythmias,
highlighting the safety, efficacy and potential therapeutic utility
of CXL-1020 for the treatment of cardiovascular disease, where
responsiveness to NO• is diminished (Sabbah et al., 2013).
These discoveries have led to the development of other HNO
donors with greater tolerability and more suitable half-lives for
therapeutic use in humans (Hartman et al., 2018). Of these, the
HNO donor BMS-986231 (half-life; 40–144 min), has been
shown to enhance cardiac contractile and relaxant responses,
while promoting vasodilation and reducing myocardial oxygen
consumption in canine models of heart failure (Hartman et al.,
2018). Moreover, in a phase I clinical trial in healthy individuals,
BMS-986231 (24- or 48-hour intravenous infusion) was well
tolerated, as the only drug-related adverse event reported was the
development of headaches, which were alleviated following
hydration, and are a common side effect of vasodilator therapy
(Cowart et al., 2019). Further, the vasodilator capacity of BMS-
986231 was evident with the HNO donor causing dose-
dependent reductions in systolic and diastolic blood pressure,
which were sustained during infusion, and returned to baseline
following infusion cessation (Cowart et al., 2019). Similar
findings were also observed in patients with heart failure,
where BMS-986231 reduced pulmonary arterial systolic and
diastolic pressure, while decreasing total peripheral vascular
resistance (Tita et al., 2017). Importantly, these hemodynamic
changes were not associated with changes in heart rate or the
presence of arrhythmias (Tita et al., 2017). In the StandUP-AHF
study (Study Assessing Nitroxyl Donor Upon Presentation with
Acute Heart Failure), patients hospitalized with heart failure with
reduced ejection fraction (HF-rEF) will receive intravenous
infusions of BMS-986231 at various doses or placebo for 48 h
(Felker et al., 2019). The results of this multicenter, randomized,
double-blind, placebo-controlled clinical trial will provide
further information about the safety and tolerability of HNO
donors with regard to hypotension (Felker et al., 2019).Frontiers in Pharmacology | www.frontiersin.org 12Whilst the poor aqueous solubility of BMS-986231 limits its
clinical use to intravenous administration, orally bioavailable
HNO donors are on the horizon (Tita et al., 2017). CXL-1036 is
an orally available HNO donor that also has a half-life (30
minutes) suitable for in vivo use and has been shown to
enhance cardiac contraction and relaxation, and reduce
myocardial demand, without altering heart rate in a canine
model of heart failure (del Rio et al., 2014).
To date, much of the focus of HNO donors has been on their
therapeutic potential in the treatmentof acutedecompensatedheart
failure. However, the novel vaso- and cardio-protective properties
of HNO highlight the therapeutic potential of HNO donors in the
treatment of a range of vascular and cardiac pathologies,
particularly where NO• signaling and responsiveness is impaired,
such as in T2DM. We eagerly await future studies which will
examine the ability for HNO donors to overcome NO• resistance
in patients with T2DM, and alleviate cardiovascular complications
associated with this disease.CONCLUSION
A loss in the generation, bioavailability and responsiveness to
vasoprotective NO• is a key contributor to the cardiovascular
dysfunction and propensity towards acute myocardial ischemia
associated with T2DM. Underpinning the impairment in NO•
signaling (termed NO• resistance) is an increase in oxidative
stress, driven predominantly by hyperglycemia. The impact of
elevated ROS generation is far reaching, leading not only to
impaired vasodilator and anti-aggregatory capacity, but ab initio
reduction in therapeutic utility of NO•-based therapeutics. NO•
resistance constitutes an independent risk factor for subsequent
cardiovascular morbidity and mortality, and there is an urgent
need to treat diabetes associated endothelial dysfunction and
NO• resistance. Although perhexiline, statins and some ACE
inhibitors have shown promise in their ability to improve
hemodynamic and vasodilator responses in diabetes, there are
limitations associated with their use in emergency treatment of
cardiovascular disorders. HNO donors, however, present novel
pharmacological properties, including circumvention of NO•
resistance, which may facilitate a new therapeutic approach to
treat diabetes-associated cardiovascular complications.AUTHOR CONTRIBUTIONS
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of HNO over NȮ. Am. J. Physiol. - Hear. Circ. Physiol. 305, H365–H377.
doi: 10.1152/ajpheart.00495.2012
Ito, H., Nakashima, M., Meguro, K., Furukawa, H., Yamashita, H., Takaki, A., et al.
(2015). Flow mediated dilatation is reduced with the progressive stages of
glomerular filtration rate and albuminuria in type 2 diabetic patients without
coronary heart disease. J. Diabetes Res. 2015, 1–9. doi: 10.1155/2015/728127
Jones, D. A., Pellaton, C., Velmurugan, S., Rathod, K. S., Andiapen, M.,
Antoniou, S., et al. (2015). Randomized phase 2 trial of intracoronary nitrite
during acute myocardial infarction. Circ. Res. 116, 437–447. doi: 10.1161/
CIRCRESAHA.116.305082
Kövamees, O., Shemyakin, A., and Pernow, J. (2016). Amino acid metabolism
reflecting arginase activity is increased in patients with type 2 diabetes and
associated with endothelial dysfunction. Diabetes Vasc. Dis. Res. 13, 354–360.
doi: 10.1177/1479164116643916
Kahlberg, N., Qin, C. X., Anthonisz, J., Jap, E., Ng, H. H., Jelinic, M., et al. (2016).
Adverse vascular remodelling is more sensitive than endothelial dysfunction to
hyperglycaemia in diabetic rat mesenteric arteries. Pharmacol. Res. 111, 325–
335. doi: 10.1016/j.phrs.2016.06.025
Kass, D. A., Takimoto, E., Nagayama, T., and Champion, H. C. (2007).
Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc. Res. 75,
303–314. doi: 10.1016/j.cardiores.2007.02.031May 2020 | Volume 11 | Article 727
Velagic et al. Nitroxyl to Circumvent NO• ResistanceKeceli, G., Majumdar, A., Thorpe, C. N., Jun, S., Tocchetti, C. G., Lee, D. I., et al.
(2019). Nitroxyl (HNO) targets phospholamban cysteines 41 and 46 to
enhance cardiac function. J. Gen. Physiol. 151, 758–770. doi: 10.1085/
jgp.201812208
Kemp-Harper, B. K., and Schmidt, H. H. H. W. (2009). “cGMP in the
vasculature,”. Eds. H. H. H. W. Schmidt, F. Hofmann and J.-P. Stasch
(Berlin, Heidelberg: Springer Berlin Heidelberg), 447–467. doi: 10.1007/978-
3-540-68964-5_19
Kemp-Harper, B. K., Horowitz, J. D., and Ritchie, R. H. (2016). Therapeutic
potential of nitroxyl (HNO) donors in the management of acute
decompensated heart failure. Drugs 76, 1337–1348. doi: 10.1007/s40265-016-
0631-y
Kemp-Harper, B. K. (2011). Nitroxyl (HNO): A novel redox signaling molecule.
Antioxid. Redox Signal. 14, 1609–1613. doi: 10.1089/ars.2011.3937
Kennedy, J. A., Beck-Oldach, K., McFadden-Lewis, K., Murphy, G. A., Wong,
Y. W., Zhang, Y., et al. (2006). Effect of the anti-anginal agent, perhexiline, on
neutrophil, valvular and vascular superoxide formation. Eur. J. Pharmacol. 531,
13–19. doi: 10.1016/j.ejphar.2005.11.058
Kizub, I. V., Klymenko, K. I., and Soloviev, A. I. (2014). Protein kinase C in
enhanced vascular tone in diabetes mellitus. Int. J. Cardiol. 174, 230–242.
doi: 10.1016/j.ijcard.2014.04.117
Ko, M. J., Jo, A. J., Kim, Y. J., Kang, S. H., Cho, S., Jo, S. H., et al. (2019). Time- and
dose-dependent association of statin use with risk of clinically relevant new-
onset diabetes mellitus in primary prevention: a nationwide observational
cohort study. J. Am. Hear. Assoc. 8, e011320. doi: 10.1161/jaha.118.011320
Kohr, M. J., Kaludercic, N., Tocchetti, C. G., Gao, W. D., Kass, D. A., Janssen,
P. M. L., et al. (2010). Nitroxyl enhances myocyte Ca2+ transients by
exclusively targeting SR Ca2+-cycling. Front. Biosci. - Elit. 2 E, 614–626.
doi: 10.2741/e118
Korkmaz, Y., Roggendorf, H. C., Siefer, O. G., Seehawer, J., Imhof, T.,
Plomann, M., et al. (2018). Downregulation of the a1- and b1-subunit of
sGC in arterial smooth muscle cells of OPSCC Is HPV-Independent. J. Dent.
Res. 97, 1214–1221. doi: 10.1177/0022034518774531
Kovanen, P. T., and Bot, I. (2017). Mast cells in atherosclerotic cardiovascular
disease - Activators and actions. Eur. J. Pharmacol. 816, 37–46. doi: 10.1016/
j.ejphar.2017.10.013
Kovanen, P. T., Maija, K., and Timo, P. (1995). Infiltrates of activated mast cells at
the site of coronary atheromatous erosion or rupture in myocardial infarction.
Circulation 92, 1084–1088. doi: 10.1161/01.CIR.92.5.1084
Laine, P., Kaartinen, M., Penttilä, A., Panula, P., Paavonen, T., and T, K. P. (1999).
Association between myocardial infarction and the mast cells in the adventitia
of the infarct-related coronary artery. Circulation 99, 361–369. doi: 10.1161/
01.CIR.99.3.361
Lee, K. H., Lee, S. R., Cho, H., Woo, J. S., Kang, J. H., Jeong, Y. M., et al. (2017).
Cardioprotective effects of PKG activation by soluble GC activator, BAY 60-
2770, in ischemia-reperfusion-injured rat hearts. PloS One 12, 1–12.
doi: 10.1371/journal.pone.0180207
Lees, C., Jurkovic, D., Zaidi, J., and Campbell, S. (1998). Unexpected effect of a
nitric oxide donor on uterine artery Doppler velocimetry in oligomenorrheic
women with polycystic ovaries. Ultrasound Obstet. Gynecol. 11, 129–132.
doi: 10.1046/j.1469-0705.1998.11020129.x
Leo, C. H., Joshi, A., Hart, J. L., and Woodman, O. L. (2012). Endothelium-
dependent nitroxyl-mediated relaxation is resistant to superoxide anion
scavenging and preserved in diabetic rat aorta. Pharmacol. Res. 66, 383–391.
doi: 10.1016/j.phrs.2012.07.010
Lima, B., Forrester, M. T., Hess, D. T., and Stamler, J. S. (2010). S-nitrosylation in
cardiovascular signaling. Circ. Res. 106, 633–646. doi: 10.1161/
CIRCRESAHA.109.207381
Lin, E. Q., Irvine, J. C., Cao, A. H., Alexander, A. E., Love, J. E., Patel, R., et al.
(2012). Nitroxyl (HNO) stimulates soluble guanylyl cyclase to suppress
cardiomyocyte hypertrophy and superoxide generation. PloS One 7, 6–16.
doi: 10.1371/journal.pone.0034892
Lindholm, M. G., Boesgaard, S., Torp-Pedersen, C., and Kober, L. (2005). Diabetes
mellitus and cardiogenic shock in acute myocardial infarction. Eur. J. Heart
Fail. 7, 834–839. doi: 10.1016/j.ejheart.2004.09.007
Lob, H., Rosenkranz, A. C., Breitenbach, T., Berkels, R., Drummond, G., and
Roesen, R. (2006). Antioxidant and nitric oxide-sparing actions ofFrontiers in Pharmacology | www.frontiersin.org 15dihydropyridines and ACE inhibitors differ in human endothelial cells.
Pharmacology 76, 8–18. doi: 10.1159/000088854
Lorenzi, M. (2007). The polyol pathway as a mechanism for diabetic retinopathy:
attractive, elusive, and resilient. Exp. Diabetes Res. 2007, 61038. doi: 10.1155/
2007/61038
Lund, T., Svindland, A., Pepaj, M., Jensen, A.-B., Berg, J. P., Kilhovd, B., et al.
(2011). Fibrin(ogen) may be an important target for methylglyoxal-derived
AGE modification in elastic arteries of humans. Diabetes Vasc. Dis. Res. 8, 284–
294. doi: 10.1177/1479164111416831
Lundberg, J. O., Gladwin, M. T., and Weitzberg, E. (2015). Strategies to increase
nitric oxide signalling in cardiovascular disease. Nat. Rev. Drug Discovery 14,
623–641. doi: 10.1038/nrd4623
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